NASH resolves, fibrosis improves in 22% treated with growth factor analogue

Fibroblast growth factor 19 analogue aldafermin showed dose- and duration-dependent reduction in liver fat with resolution of non-alcoholic steatohepatitis in more than one-fifth of cases, according to a presenter at the Digital International Liver Congress.“Ultimately, looking at the study from cohort 4, the primary endpoint was met. Clinically significant improvements in histology regulatory endpoints of fibrosis improvement, resolution of NASH and the composite endpoint requiring achievement of both are very positive,” Stephen Harrison, MD, medical director of PinnacleRead More

Share on facebook
Share on twitter
Share on linkedin